Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics


Tenax Therapeutics, Inc. (TENX): $1.60

0.04 (+2.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TENX Stock Price Chart Interactive Chart >

Price chart for TENX

TENX Price/Volume Stats

Current price $1.60 52-week high $3.68
Prev. close $1.56 52-week low $0.80
Day low $1.47 Volume 144,441
Day high $1.74 Avg. volume 953,859
50-day MA $1.56 Dividend yield N/A
200-day MA $1.90 Market Cap 40.32M

Tenax Therapeutics, Inc. (TENX) Company Bio


Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.


TENX Latest News Stream


Event/Time News Detail
Loading, please wait...

TENX Latest Social Stream


Loading social stream, please wait...

View Full TENX Social Stream

Latest TENX News From Around the Web

Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.

TENX: Second Quarter Results

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2021 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2021 results via the issuance of a press release and the filing of Form 10-Q to the SEC on August 16, 2021. Highlights for the second quarter and to-date: ➢ Publication of HELP trial results - April 2021 ➢

Yahoo | September 20, 2021

Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MORRISVILLE, N.C., September 09, 2021--Tenax Therapeutics, Inc. (Nasdaq: TENX) announced company to present at H.C. Wainwright Conference September 13-15, 2021

Yahoo | September 9, 2021

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C., August 17, 2021--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces second quarter 2021 financial results and provides business update.

Yahoo | August 17, 2021

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study

Business Wire | August 12, 2021

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.

Business Wire | August 5, 2021

Read More 'TENX' Stories Here

TENX Price Returns

1-mo -1.23%
3-mo -23.08%
6-mo -16.67%
1-year 2.56%
3-year -69.58%
5-year -96.55%
YTD -13.98%
2020 31.91%
2019 16.53%
2018 -87.65%
2017 -74.87%
2016 -40.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1045 seconds.